drugset / Trial / NCT07330531

Drug-drug Interaction Study of Rifampin and Anaprazole Sodium

NCT07330531

Phase 4 Not yet recruiting 24 enrolled Xuanzhu Biopharmaceutical Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

A drug-drug interaction study designed to evaluate the drug-drug interaction between rifampin capsules and anaprazole sodium enteric-coated tablets in healthy adult subjects

Timeline

Start
2026-01-04
Primary completion
2026-02-05
Completion
2027-07-21

Drugs

EvaluationDrugModalityDoseRoute
Subject Anaprazole Other / unclassified 60 mg Oral
Subject Rifampin Small molecule 600 mg Oral

Indications

No indication recorded.